ABOS Earnings Prediction
The chart below shows how ABOS performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ABOS sees a +1.70% change in stock price 10 days leading up to the earnings, and a -7.42% change 10 days following the report. On the earnings day itself, the stock moves by +2.06%. This data can give you a slight idea of what to expect for the next quarter's release.
ABOS Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
--
--
--
Gross Margin
--
--
--
Operating Margin
--
--
--
Net Margin
--
--
--
EPS
-0.50
-108.33%
47.06%
No Data Available
ABOS Earnings Analysis
Acumen Pharmaceuticals, Inc. Common Stock Corporation (ABOS.O) Earnings Conference Call
Positive
Enrollment Rate Acceleration: The enrollment rate for the ALTITUDE-AD Phase II study has progressed far more rapidly than anticipated, with expectations to complete enrollment in the first half of 2025.
Cash and Marketable Securities: As of September 30, we had approximately $259 million in cash and marketable securities on the balance sheet, expected to last into the first half of 2027.
R&D Expense Increase: R&D expenses were $27.2 million in the third quarter, primarily due to increased spending to support the ALTITUDE-AD trial.
Clinical Development Progress: The first patient enrolled in the ALTITUDE-AD study in the second quarter of this year, indicating strong progress in our clinical development efforts.
Effective Trial Site Collaborations: We have established effective collaborations with top trial sites across all three regions, contributing to a promising enrollment rate.
Negative
Cash Reserves and Runway: As of September 30, we had approximately $259 million in cash and marketable securities on the balance sheet and continue to expect that cash runway to last into the first half of 2027.
R&D Expense Increase: R&D expenses were $27.2 million in the third quarter. The increase over the prior year was primarily due to the increased spending to support the ALTITUDE-AD trial.
Quarterly Operational Loss: This led to a loss from operations of $32.3 million and a net loss of $29.8 million in the quarter.
Net Cash Burn Analysis: Our net cash burn in the quarter was approximately $23 million, which includes the impact of $2.5 million in net interest income, $2.4 million in non-cash stock compensation expense and the impact of expense accruals.
Phase I Study Progress: We have continued to progress our Phase I study of subcutaneous sabirnetug and anticipate the topline results for this study will be available in the first quarter of 2025.
ABOS FAQs
How does ABOS typically perform around its earnings report dates?
Is Acumen Pharmaceuticals, Inc. (ABOS) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
ABOS Earning Call Sentiment
Acumen Pharmaceuticals, Inc. (ABOS) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
ABOS.O
-1.35%Positive
The earnings call reveals mixed signals. While the company maintains a solid cash position and efficient trial enrollment, it faces significant financial losses and competitive pressures. The Q&A section highlights uncertainties around future trial data and market adoption. Despite the positive enrollment progress and cash runway, lack of clear guidance on subcutaneous development and existing market competition temper optimism. With no major catalysts or guidance changes, the stock price is likely to remain stable over the next two weeks.